Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
City of Hope Medical Center
City of Hope Medical Center
University of Washington
National Cancer Institute (NCI)
Mayo Clinic
City of Hope Medical Center
Roswell Park Cancer Institute
Washington University School of Medicine
Roswell Park Cancer Institute
Northwestern University
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)